Actualización acerca del uso de HCQ, CQ o LPV/r con relación a la COVID-19
Letters to the Editor
Keywords:
enfermedades transmisibles, coronavirus, virus del SARSAbstract
Letter to Editor
References
Farfán Cano G. A perspective about coronavirus disease 2019 (COVID-19). INSPILIP [Internet]. 2020;4(2):1-23. Available from: https://www.inspilip.gob.ec/?p=3167.
Ministerio de Salud Pública del Ecuador. Consenso interino multidisciplinario informado en la evidencia sobre el tratamiento de COVID-19 [Versión 2.1]. Ecuador: MSP; 2020 p. 40-50.
Chang R, Sun W. Repositioning Chloroquine as ideal antiviral prophylactic against COVID-19 - Time is Now. 2020. Preprint. DOI: 10.20944/preprints202003.0279.v1
Rosenberg E. & cols. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA The Journal of the American Medical Association. 2020; DOI: 10.1001/jama.2020.8630.
Silva Rojas, G, Farfán-Cano, G, Silva-Rojas, K, Espín Bayona, D, Espín Bayona, C, Farfán Cano, H. ¿Profilaxis con cloroquina y/o hidroxicloroquina para COVID-19? [Preprint]. 2020. DOI: 10.13140/RG.2.2.14036.14728.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G et al. A Trial of Llopinavir–ritonavir in adults hospitalized with severe COVID-19. New England Journal of Medicine [Internet]. 2020;382(19):1787-1799. DOI: http://10.1056/nejmoa2001282
Verdugo-Paiva F, Izcovich A, Ragusa M, Rada G. Lopinavir/ritonavir for the treatment of COVID-19: A living systematic review protocol. [Internet]. 2020 [cited 1 May 2020];. Available from: https://doi.org/10.1101/2020.04.11.20062109.
Liu X, Chen H, Shang Y, Zhu H, Chen G, Chen Y et al. Efficacy of chloroquine and lopinavir/ritonavir in mild/general COVID-2019: a prospective, open-label, multicenter randomized controlled clinical study. [Internet]. 2020 [cited 1 May 2020];. Available from: https://doi.org/10.21203/rs.3.rs-16392/v1
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Science Ecuador
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.
This is a human-readable summary of (and not a substitute for) the license.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
